Sugi Predict

Sugi Predict / Compounds / SCHEMBL1009435

SCHEMBL1009435

SCHEMBL1009435

CC(C)(C)OC(=O)N1CCc2[nH]nc(C(F)(F)F)c2C1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 3/20 0.46
▸ DPP8 Q6V1X1 3/20 0.46
▸ DPP7 Q9UHL4 3/20 0.46
▸ DPP9 Q86TI2 2/20 0.46
▸ SPR P35270 1/20 0.42
▸ RBP4 P02753 3/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ CREBBP Q92793 5/20 0.41
▸ EP300 Q09472 4/20 0.41
▸ BRD4 O60885 3/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ ADORA1 P30542 1/20 0.40
▸ NR1H2 P55055 1/20 0.40
▸ CFTR P13569 1/20 0.38
▸ PARP1 P09874 1/20 0.37
▸ TNKS2 Q9H2K2 1/20 0.37
▸ PARP2 Q9UGN5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10296218 0.91 ESR2 (0.43) ESR2CREBBPEP300BRD4MAPK1
SCHEMBL1424003 0.90 DPP4 (0.46) DPP4DPP8DPP7DPP9RBP4
SCHEMBL17868704 0.89 ESR2 (0.41) ESR2CREBBPEP300BRD4MAPK1
SCHEMBL21995320 0.88 NR1H2 (0.38) DPP4DPP8DPP7DPP9SPR
SCHEMBL17868584 0.85 CREBBP (0.41) DPP4DPP8DPP7DPP9ESR2
SCHEMBL10095038 0.85 ESR2 (0.42) ESR2CREBBPEP300BRD4MAPK1
SCHEMBL17868654 0.83 ESR2 (0.46) ESR2CREBBPEP300BRD4MAPK1
SCHEMBL14971269 0.83 ESR2 (0.43) ESR2CREBBPEP300BRD4MAPK1
SCHEMBL14970423 0.83 MAPK1 (0.56) DPP4DPP8DPP7DPP9SPR
SCHEMBL17785628 0.82 ESR2 (0.42) ESR2CREBBPEP300BRD4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 — — EP disclosed
US-20240383875-A1 Benzimidazole Pyridine Derivatives HOFFMANN-LA ROCHE INC. (US) 2024-11-21 — — US disclosed
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2024-11-14 — — US disclosed
CN-115215886-B Compounds and compositions as endosomal Toll-like receptor inhibitors 诺华股份有限公司 2024-10-11 — — CN disclosed
CN-118591534-A Novel benzimidazole pyridine derivatives 豪夫迈·罗氏有限公司 2024-09-03 — — CN disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 — — WO disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
CN-115215886-A Compounds and compositions as endosomal Toll-like receptor inhibitors 诺华股份有限公司 2022-10-21 — — CN disclosed
EP-4059934-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS Novartis AG (CH) 2022-09-21 — — EP disclosed
CN-109641899-B Compounds and compositions as endosomal Toll-like receptor inhibitors 诺华股份有限公司 2022-07-22 — — CN disclosed
EP-1589969-A4 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO INC (US) 2008-08-13 — — EP disclosed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 — — WO disclosed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 — — WO disclosed
US-7265128-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2007-09-04 — — US disclosed
EP-1691810-A1 SUBSTITUTED PIPERAZINES ChemoCentryx Inc (US) 2006-08-23 — — EP disclosed
US-20060106218-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2006-05-18 — — US disclosed
US-20060069116-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME LLC 2006-03-30 — — US disclosed
EP-1589969-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co. Inc. (US) 2005-11-02 — — EP disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 — — WO disclosed
WO-2004064778-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO. INC. (US) 2004-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 DPP4 649/4885DPP8 831/4885DPP7 725/4885
US-20060106218-A1 Substituted piperazines CCR1, CCR3, CCRL2 DPP4 2464/4885DPP8 1897/4885DPP7 1494/4885
US-20240383875-A1 Benzimidazole Pyridine Derivatives H1-3, H1-2, H1-4 DPP4 1476/4885DPP8 2740/4885DPP7 2613/4885
US-20060069116-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 DPP4 1/4885DPP8 5/4885DPP7 3/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN DPP4 2011/4885DPP8 2995/4885DPP7 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.